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Immediate and delayed hypersensitivity reactions to a single dose of 
oxaliplatin 
 
Clinical Practice Points 
• Hypersensitivity reactions, occurring during or immediately following oxaliplatin 
infusions, are well documented and more commonly occur after multiple courses of 
therapy 
• A 69-year old Caucasian woman with stage III colon cancer commenced adjuvant 
chemotherapy with oxaliplatin and capecitabine. Ten minutes after the completion of 
the oxaliplatin infusion she experienced a severe hypersensitivity reaction. Following 
treatment with corticosteroids, anti-histamines and bronchodilators symptoms 
resolved. Nineteen hours later, a similar reaction occurred. 
• A review of the literature found two similar cases of delayed reactions to oxaliplatin 
occurring 20 and 10 hours after infusion respectively. The first case occurred after the 
initial dose and again with cycle 2. The second case happened following the sixth 
infusion. 
• This is the first reported case of immediate and delayed hypersensitivity reactions 
occurring following the initial dose of oxaliplatin. 
 
Keywords: Bronchospasm; chemotherapy; hypersensitivity reaction; initial dose; oxaliplatin 
 
Introduction 
Oxaliplatin is a third-generation platinum compound widely used in combination with 
fluropyrimidine agents in the treatment of colorectal cancer and a variety of other 
malignancies. Like other platinum agents, oxaliplatin is associated with hypersensitivity 
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reactions (HSR).  The overall incidence of HSR is 13%, with the rate of severe reactions 
approximately 0.5%.1 HSR following oxaliplatin may occur within minutes of its 
administration and with any cycle of therapy. The incidence increases with multiple courses 
of therapy, indicating that prolonged exposure to oxaliplatin has a role in patient 
sensitization.2 In a recent case series analysis, life-threatening severe anaphylactic reactions 
(SAR) to oxaliplatin were defined as side effects including symptomatic bronchospasm, 
allergy-related edema/angioedema, hypotension or anaphylaxis requiring hospitalization and 
medical intervention.3  In addition to the 8 patents from this case series, a literature review of 
23 English language retrospective studies from 1997 to 2011, identified 59 further cases.3 
The median cycles of oxaliplatin given before SAR developed was 10 (range, 2-29). Three 
fatalities (4.5%) were reported.  We wish to report an unusual presentation of hypersensitivity 
to the initial dose of oxaliplatin, consisting of severe respiratory symptoms which occurred 
immediately after completion of the infusion and recurred again 19 hours later. 
Case Report 
A 69-year old Caucasian woman underwent a left hemicolectomy for a non-obstructing mass 
in the caecum. Histology showed a moderately differentiated adenocarcinoma extending 
through the bowel wall into the sub-serosa. Two of 9 sampled lymph nodes contained 
metastatic carcinoma. There was no evidence of metastatic disease on staging. Medical 
history included asthma, osteoarthritis and anxiety. Her only medications were salbutamol 
and temazepam, both only as required. There was no history of allergies. Adjuvant 
chemotherapy for Stage III disease was commenced with XELOX (oxaliplatin 130 mg/m2 IV 
and capecitabine 1000 mg/m2 given orally twice a day for 14 days); repeated every 3 weeks. 
Ondansetron and dexamethasone were prescribed for 3 days as anti-emetics.  Ten minutes 
after completion of the 2 hour infusion of oxaliplatin, the patient complained of tightness in 
the throat and severe shortness of breath. Stridor and swelling of the lips were observed. 
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Blood pressure was slightly elevated. Bronchospasm and laryngeal spasm were diagnosed 
and immediate treatment with hydrocortisone 100 mg IV given. Following promethazine 12.5 
mg IV and a further 100mg IV of hydrocortisone, symptoms quickly resolved. Nebulized 
salbutamol and ipratropium were administered. No potential precipitating factors, such as 
cold drinks, were noted. The patient was admitted overnight for observation. Next morning, 
19 hours after completion of the oxaliplatin infusion, a similar, though less severe, episode 
occurred. Symptoms included difficulty in breathing, hoarse voice and swelling of the 
tongue. Following treatment with IV promethazine, symptoms resolved. Dexamethasone, for 
prevention of nausea, and nebulized ipratropium had been given several hours before and 
these may have contributed to the less severe presentation. The only other medication taken 
was a single dose of capecitabine given 4 hours prior to the HSR. Standard haematological 
and biochemical blood tests taken following the reactions showed no abnormalities. 
Unfortunately IgE and tryptase levels were not measured at the time of the reactions. She 
recovered well with no subsequent problems. The patient refused further treatment with 
oxaliplatin and declined all other adjuvant chemotherapy options. 
Discussion 
HSR to oxaliplatin are rarely seen following the first administration of the drug. In a 
retrospective review of 1224 patients exposed to oxaliplatin-containing chemotherapy 
regimens, Polyzos et al reported 308 cases of hypersensitivity, with 113 termed severe.4 Only 
5 patients (0.4%) developed an acute severe reaction during the first three courses of 
treatment.  
  Two similar cases of HSR, with a delayed presentation after oxaliplatin 
administration, have been reported in the literature. An 81-year old Caucasian woman was 
treated with XELOX for metastatic colorectal cancer. Twenty hours after the first infusion of 
oxaliplatin, she acutely developed serious dyspnoea with an inspiratory stridor and peripheral 
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cyanosis.5 Following pre-medication with dexamethasone and anti-histamines, a second cycle 
of oxaliplatin was administered over 6 hours without incident. However, 20 hours later the 
same reaction with dyspnoea and stridor again occurred. Further treatment with oxaliplatin 
was discontinued. A 46-year old man with metastatic colorectal cancer received five courses 
of combination chemotherapy with oxaliplatin without incident. However, following the sixth 
dose he experienced a delayed severe HSR reaction.6 Ten hours after oxaliplatin 
administration, the patient developed dysesthesia and laryngeal spasm. Symptoms 
progressively regressed without treatment. Successful re-challenge with oxaliplatin was 
achieved with an increase in dilution and infusion time. 
 Because HSR reactions to platinum compounds are usually seen after multiple cycles, 
the mechanism  is thought to be due to a Type I response, mediated by IgE.3,7 Immune-
mediated thrombocytopenia and haemolytic anemia have also been reported with oxaliplatin 
indicating a Type II hypersensitivity mediated by IgG and IgM.7-10 IgG mediated Type III 
reactions, resulting in symptoms such as chronic uricaria and fever, have been documented7. 
Delayed reactions which can occur hours or even days after an oxaliplatin infusion have been 
reported. These are Type IV HSR mediated through T-cells and can present as contact 
dermatitis.12 
 The exact mechanism of our patient’s reaction is unclear, but may involve immune-
mediated and non-immunologic mechanisms possibly including Type 1 and Type IV HSR.7,8 
Prick and intradermal skin tests have been beneficial in detecting drug-specific IgE with 
platinum salts.8 Skin testing was deemed unnecessary in our patient as we didn’t intend to 
continue oxaliplatin therapy and the possible risk of anaphylaxis which has been reported 
following skin testing.14 It has also been postulated that excess serotonin may play a role in 
inducing bronchospasm through serotonin receptors  I and II.15 
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 Strategies such as premedication with corticosteroids and antihistamines and 
prolongation of the infusion rate have been used to prevent SAR after oxaliplatin use.3,16 
Densensitization protocols have also been employed successfully.16-18  However, despite 
these interventions, reactions have still occurred.  Prior to making her decision to cease 
adjuvant chemotherapy, our patient was made fully aware of the options for continuing 
oxaliplatin-based chemotherapy and the potential risk of further serious and even fatal HSR 
even with preventative strategies. She was also given the option of continuing chemotherapy 
without oxaliplatin using single agent treatment with capecitabine or infusional fluorouracil 
and understood the potential survival benefits.  
Conclusion 
This is the first reported case of an immediate acute HSR with the initial dose of oxaliplatin 
followed by a similar delayed reaction 19 hours later. Due to the increasing clinical use of 
oxaliplatin in the adjuvant and metastatic settings, clinicians should be aware of this unusual, 
potentially life-threating HSR presentation. 
 
References 
1. Lee C, Gianos M, Klaustermeyer WB. Diagnosis and management of hypersensitivity 
reactions related to common chemotherapy agents. Ann Allergy Asthma Immunol 
2009; 102:179-87. 
2. Syrigou E, Syrigos K, Saif MW. Hypersensitivity reactions to oxaliplatin and other 
antineoplastic agents. Curr Allergy Asthma Rep 2008; 8:56-62. 
3. Wang JH, King Tm, Chang MC, Hsu CW. Oxaliplatin-induced severe anaphylactic 
reactions in metastatic colorectal cancer: Case series analysis. World J Gastroenterol 
2012; 18:5427-33. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
4. Polyzos A, Tsavaris N, Gogas H et al. Clinical features of hypersensitivity reactions 
to oxaliplatin: a 10-year experience. Oncology 2009; 76:36-41. 
5. De Vries RS, Mattijssen EJ, van Sorge AA. Serious delayed hypersentitivity reaction 
to oxaliplatin. Ann Oncol 2006; 17:1723-4. 
6. Potenza S, Nasti G, Alessandro O, Filipelli A, Rossi F, Capuano. Severe respiratory 
symptoms to oxaliplatin infusion: a case report of delayed hypersensitivity reaction. 
Invest New Drugs 2010; 28:185-6. 
7. Makrilia N, Syrigou E, Kaklamanos I, Manolopoulos L, Saif MW. Hypersensitivity 
reactions associated with platinum antineoplastic agents: a systematic review. Met-
Based Drugs 2010; 2010:20708. 
8. Pagani M. The complex clinical picture of presumably allergic side effects to 
cytostatic drugs: Symptoms, pathomechanism, reexposure and desensitization. Med 
Clin North Am 2010; 94: 835-52. 
9. Maindrault-Goebel F, Andre T, Tournigand C et al. Allergic-type resctions to 
oxaliplatin: retrospective analysis of 42 patients. Eur J Cancer 2005; 41: 2262-7. 
10. Bautista MA, Stevens WT, Chen CS, Curtis BR, Aster RH, Hsueh CT. 
Hypersensitivity reaction and immune-mediated thrombocytopenia from oxaliplatin: 
two case reports and a review of the literature. J Hematol Oncol 2010; 3: 12. 
11. Cobo F, De Celis G, Pereira A, Latorre X, Pujadas J, Albiol S. Oxaliplatin-induced 
immune hemolytic anemia: a case report and review of the literature. Anticancer 
Drugs 2007; 18: 973-6. 
12. Ichikawa Y, Goto S, Hirokawa S et al. Allergic reactions to oxaliplatin in a single 
Institute in Japan. Japan J Clin Oncol 2009; 39; 616-20. 
13. Villee C, Tennstedt D, Marot L, Goossens A, Baeck M. Delayed urticarial with 
oxaliplatin. Contact Derm 2010; 63: 50-3. 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
14. Martin-Lazaro J, Firvida JL, Berges-Gimeno P. Anaphylaxis after oxaliplatin allergy 
skin testing. J Investig Allergol Clin Immunol 2014; 24; 267-85. 
15. Lee MY, Yang MH, Liu JH et al. Severe anaphylactic reactions in patients receiving 
oxaliplatin therapy: a rare but potentially fatal complication. Support Care Cancer 
2007; 15:89-93. 
16. Lee SY, Kang HR, Song WJ, Lee KH, Han SW, Cho SH. Overcoming oxaliplatin 
hypersensitivity: different strategies are meeded according to the severity and 
previous exposure. Cancer Chemother Pharmacol 2014; 73: 1021-9. 
17. Syrigou E, Karapanaagiotou EM, Alamara CV, Boura PG, Saif MW, Syrigos KN. 
Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of 
a desensitization protocol. Clin Colorectal Cancer 2009; 8:106-9. 
18. Cortijo-Cascajares S, Nacle-Lopez I, Garcia-Escobar I et al. Effectiveness of 
oxaliplatin desensitization protocols. Clin Transl Oncol 2013; 15:219-25. 
